Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm

Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn

Tocilizumab in GCA: what happens in the vessels? Supporting excellent work @KQuinnRheum @petercgrayson earlier at #ACR20, LV-GCA data from Blanco/Gonzalez-Gay et al. Aorta still hot at 10.8±3.7 mo. in LV-GCA on TCZ, clinical remission ≠ PET remission #ACR20 ABST1921 @RheumNow https://t.co/ngBVL4rop8

SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA

@rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts

Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP): - 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment - 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4

How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20

Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp